Treatment of multiple sclerosis by oral administration of autoantigens

• US 5,869,054 A
• Filed: 05/31/1995
• Issued: 02/09/1999
• Est. Priority Date: 06/24/1987
• Status: Expired due to Fees

• Current Assignee: Autoimmune, Inc.
• Original Assignee: Autoimmune, Inc.
• Inventors: Hafler, David A., Weiner, Howard L.
• Primary Examiner(s): ACHUTAMURTHY, PONNATHAPURA N
• Application Number:
  US08/454,832
• Time in Patent Office: 1,350 Days
• Field of Search: 424/184.1, 530/326, 530/327, 530/328, 530/329, 530/330, 530/350, 530/356, 530/387.1, 530/387.3, 530/387.5, 530/868, 514/2, 514/8, 514/12, 514/13, 514/21, 514/825, 514/868, 514/903
• US Class Current: 424/184.1
• CPC Class Codes: A61K 2039/542 oral/gastrointestinal
• CPC Class Codes: A61K 2039/543 intranasal
• CPC Class Codes: A61K 38/39 Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
• CPC Class Codes: A61K 39/0008 Antigens related to auto-immune diseases; Preparations to induce self-tolerance

Abstract

The invention is directed to a method of treating a T cell-mediated autoimmune disease in animals, including humans, by the oral or enteral administration of autoantigens, fragments of autoantigens, or analogs structurally related to those autoantigens, which are specific for the particular autoimmune disease. The method of the invention includes both prophylactic and therapeutic measures.

Claims

1. A method of treating multiple sclerosis comprising orally or enterally administering a composition comprising MBP to a human suffering from multiple sclerosis, in an amount effective to suppress autoimmune response associated with said multiple sclerosis, the suppression of said response comprising elicitation of suppressor T-cells specific to MBP.

2. The method of claim 1 wherein said treatment suppresses the symptoms of said multiple sclerosis.

3. The method of claim 1 wherein said composition is administered orally.

5. The method of claim 1 wherein said composition comprises tissue that is the target of attack in said autoimmune disease.

6. The method of claim 1 comprising administering said composition in a solid form.

7. The method of claim 1 comprising administering said composition in a semi-solid form.

8. The method of claim 1 wherein said composition further comprises a pharmaceutically acceptable carrier.

4. The method of claim I wherein said composition is administered enterally.

9. A method of treating multiple sclerosis comprising orally or enterally administering to a human suffering from multiple sclerosis an effective amount for treating multiple sclerosis of a composition comprising MBP, said treatment comprising in elicitation of suppressor T-cells.

10. The method of claim 9 wherein said composition comprises tissue that is the target of attack in said autoimmune disease.

11. The method of claim 9 comprising administering said composition in a solid form.

12. The method of claim 9 comprising administering said composition in a semi-solid form.

13. The method of claim 9 wherein said composition comprises a pharmaceutically acceptable carrier.

14. A method of treating multiple sclerosis comprising orally or enterally administering a composition comprising MBP to a human suffering from multiple sclerosis, in an amount effective to suppress autoimmune response associated with said multiple sclerosis.

15. The method of claim 14 wherein said composition comprises tissue that is the target of attack in said autoimmune disease.

16. The method of claim 14 comprising administering said composition in a solid form.

17. The method of claim 14 comprising administering said composition in a semi-solid form.

18. The method of claim 14 wherein said composition comprises a pharmaceutically acceptable carrier.

19. A method for treatment of a human suffering from multiple sclerosis comprising orally or enterally administering to said human a composition comprising MBP in an amount effective to treat said multiple sclerosis.

20. The method of claim 19 wherein said composition comprises tissue that is the target of attack in said autoimmune disease.

21. The method of claim 19 comprising administering said composition in a solid form.

22. The method of claim 19 comprising administering said composition in a semi-solid form.

23. The method of claim 19 wherein said composition comprises a pharmaceutically acceptable carrier.

24. A method of treating multiple sclerosis comprising orally or enterally administering a composition comprising a peptide fragment of MBP to a human suffering from multiple sclerosis, in an amount effective to suppress autoimmune response associated with said multiple sclerosis, wherein said peptide fragment is effective to suppress said response.

25. The method of claim 24 comprising administering said composition in a solid form.

26. The method of claim 24 comprising administering said composition in a semi-solid form.

27. The method of claim 24 wherein said peptide is synthesized.

28. The method of treating multiple sclerosis comprising orally or enterally administering a composition comprising an analog of MBP to a human suffering from multiple sclerosis, in an amount effective to suppress autoimmune response associated with said multiple sclerosis, wherein said analog is effective to suppress said autoimmune response.

29. The method of claim 28 comprising administering said composition in a semi-solid form.

30. The method of claim 28 comprising administering said composition in a solid form.